JCTA Journal of Computing Theories and Applications ISSN:3024-9104

Review Article

Harnessing Artificial Intelligence for Early Disease Detection: Opportunities and Challenges in Modern Healthcare

Achile Solomon Egbunu [1] and Akindele Michael Okedoye [2,*]

[1] Department of Computer Science, University of Alabama in Huntsville, 301 Sparkman, AL 35899, United States; e-mail : ase0016@uah.edu
[2] Department of Mathematics, College of Science, Federal University of Petroleum Resources, Effurun 330102, Nigeria; e-mail : okedoye.akindele@fupre.edu.ng
* Corresponding Author : Akindele Michael Okedoye

Abstract: Artificial Intelligence (AI) is increasingly recognized as a transformative enabler of early disease detection, with the potential to improve diagnostic accuracy, support predictive risk stratification, and advance preventive healthcare. Despite rapid methodological progress, many existing reviews remain performance-centric, offering limited insight into generalizability, ethical governance, and real-world implementation constraints. This paper presents a narrative and integrative review with an adoption-focused, translational perspective, synthesizing recent developments in AI-driven early disease detection across oncology, cardiology, neurology, and infectious disease surveillance. Drawing on peer-reviewed literature published primarily between 2016 and 2025, the review examines reported performance gains alongside persistent limitations related to data heterogeneity, population bias, explainability, and regulatory fragmentation. Through cross-sectional synthesis, we identify three recurring gaps in prior reviews: (i) overgeneralization of AI's diagnostic superiority, (ii) insufficient consideration of ethical and legal accountability, and (iii) a lack of actionable guidance for scalable clinical implementation. Integrating technical, ethical, and policy dimensions into a unified conceptual framework, this review demonstrates that while AI systems can consistently enhance diagnostic accuracy and early risk stratification in well-defined tasks, sustained clinical adoption depends on aligning technical performance with governance readiness, interpretability, and workflow integration. The analysis further highlights how implementation mechanisms—such as explainable AI, continuous post-deployment monitoring, and clinician-centered deployment strategies—mediate the translation of algorithmic innovation into real-world healthcare impact. Overall, this review provides a critical reference for researchers, clinicians, and policymakers seeking to translate AI innovation into safe, equitable, and trustworthy clinical practice.

Keywords: Artificial Intelligence; Clinical Adoption; Early Disease Detection; Explainable AI; Healthcare Governance; Machine Learning; Predictive Analytics; Translational Review.

Received: December, 21st 2025
Revised: February, 3rd 2026
Accepted: February, 4th 2026
Published: February, 20th 2026

1. Introduction

The integration of Artificial Intelligence (AI) into healthcare represents one of the most transformative technological developments of the 21st century. AI-driven systems have demonstrated a strong capacity to process complex clinical data, identify subtle diagnostic patterns, and support medical decision-making beyond conventional human capabilities. Among their most impactful applications is early disease detection, where AI systems can identify or predict pathological conditions before clinical symptoms become apparent. Early diagnosis is widely recognized as a critical factor in improving treatment outcomes, reducing healthcare costs, and enhancing patient quality of life.

Despite rapid advances in AI methodologies, seamless clinical adoption remains limited. Persistent challenges related to data heterogeneity, ethical accountability, model generalizability, and regulatory readiness continue to constrain real-world deployment. This paper examines how AI is reshaping early disease detection and outlines pathways for responsible, equitable, and clinically sustainable implementation.

1.1. Background and Scope of Prior Reviews

Artificial intelligence has evolved from early rule-based expert systems toward data-driven machine learning and deep learning approaches capable of extracting predictive insights from high-dimensional healthcare data. Foundational studies demonstrated that machine learning could predict clinical outcomes using electronic health records (EHRs), signaling a paradigm shift from reactive to predictive medicine [1]. Subsequent work documented the progression of AI across diagnostic domains, including radiology, pathology, and cardiology, as data-driven learning models replaced manually engineered decision rules [2]. The emergence of deep learning—particularly convolutional neural networks—further accelerated progress, enabling near-human performance in imaging-based diagnosis across multiple clinical tasks [3], [4].

Landmark validation studies marked the transition from proof-of-concept systems to clinical deployment. Abràmoff et al. reported the first FDA-cleared autonomous AI system for diabetic retinopathy screening, demonstrating safe operation without direct clinician oversight [5]. McKinney et al. [6] subsequently validated AI-assisted breast cancer screening across international cohorts, reporting improved cancer detection with reduced false-positive rates. More recent studies have extended AI applications beyond binary detection toward longitudinal risk prediction, integrating imaging, clinical history, and demographic data into multimodal predictive models [7].

Parallel to these empirical advances, a growing body of review literature has synthesized the state of AI in healthcare. Comprehensive reviews have consolidated evidence on diagnostic performance while consistently identifying unresolved challenges related to data bias, limited external validation, and difficulties in real-world deployment [8], [9]. Recent analytical reviews further highlight the emergence of generative AI and large-scale foundation models, which enable multimodal data fusion, automated clinical summarization, and advanced decision-support across radiology, emergency medicine, and remote care environments [8], [10], [11]. While these models expand the representational capacity of traditional deep learning systems, they also introduce new risks, including opacity, hallucination, and governance challenges when deployed in safety-critical clinical contexts [10].

Beyond algorithmic innovation, multidisciplinary reviews increasingly emphasize that ethical, regulatory, and generalizability considerations are central determinants of AI's clinical legitimacy. Empirical evidence demonstrates that algorithmic bias—often arising from cost-based proxies or unrepresentative training datasets—can systematically underestimate disease severity in marginalized populations [12]. Similarly, models trained on homogeneous datasets frequently fail to generalize across institutions, geographic regions, and disease prevalences [13]. Ethical analyses argue that explainability should be understood not merely as a technical enhancement but as a socio-clinical requirement linked to informed consent, professional accountability, and trust [14], [15]. However, excessive or poorly aligned transparency may paradoxically reduce clinical usability when explanations conflict with established diagnostic reasoning [16]. Regulatory frameworks have begun to evolve in response to these concerns, with initiatives such as the U.S. FDA's Good Machine Learning Practice (GMLP) principles and adaptive oversight for Software as a Medical Device (SaMD) [17], alongside the European Union AI Act, which classifies medical AI as a high-risk technology requiring conformity assessment and post-market surveillance [18].

Despite the growing volume of literature, most existing reviews remain performance-centric and modality-specific. They typically assess diagnostic accuracy or computational innovation in isolation, without integrating ethical accountability, regulatory feasibility, data governance, and implementation readiness into a unified analytical framework. Consequently, clinicians, healthcare administrators, and policymakers lack coherent criteria for evaluating when and under what conditions AI systems are suitable for sustained real-world deployment. This review addresses this limitation by explicitly linking technical capability, ethical and regulatory constraints, and implementation strategies along a translational pathway from algorithm development to routine clinical adoption. Recent implementation science research further underscores that AI's transformative potential depends not only on technical performance but also on governance, integration, and adoption readiness [19].

1.2. Limitations of Existing Reviews: What Is Missing?

Despite an expanding corpus of reviews on AI in healthcare, several critical gaps remain. Most existing reviews emphasize algorithmic performance metrics while under-addressing translational challenges such as regulatory approval pathways, ethical accountability, and post-deployment monitoring. Reviews frequently focus on single data modalities—such as medical imaging or EHRs—while overlooking integrative pipelines that combine imaging, genomics, wearable sensors, and real-time physiological data [8], [20].

Moreover, although explainable AI (XAI) has received increasing attention, many reviews treat explainability as a purely technical add-on rather than as a socio-clinical requirement embedded within medical accountability structures [14], [21]. Failure modes, reproducibility limitations, and the restricted external validation of FDA-approved AI systems are also rarely examined in depth [22], [23]. As a result, existing reviews offer limited guidance for stakeholders seeking to evaluate AI readiness for real-world clinical integration.

1.3. Objective and Contribution of This Review

This review aims to address these unresolved gaps by providing a holistic, responsibility-driven synthesis of AI for early disease detection. Unlike prior reviews, this work:

- Integrates technical performance, ethical governance, and regulatory frameworks within a single narrative;
- Synthesizes recent advances in generative AI, quantum-enhanced learning, and hybrid classical–deep architectures [10], [24]–[26];
- Evaluates generalizability, bias mitigation, and explainability as prerequisites—rather than afterthoughts—for clinical deployment;
- Proposes implementation-oriented strategies for responsible integration across diverse healthcare systems.
- By bridging algorithmic innovation with clinical accountability, this review advances a translational roadmap for safe, equitable, and sustainable AI adoption.

1.4. Conceptual Framework for AI in Early Disease Detection

The proposed conceptual framework (Figure 1) presents a generalized pipeline for AI-driven early disease detection, illustrating commonly shared functional components across contemporary healthcare AI systems.



Figure 1. Conceptual framework of the AI-driven early disease detection system.

The framework encompasses five interconnected phases—data input, preprocessing, model training, inference, and clinical feedback—that collectively transform heterogeneous healthcare data into actionable clinical insights. Importantly, this framework is intended as a representative reference model rather than a prescriptive clinical workflow, acknowledging that disease-specific and institutional implementations may vary.

The data input phase aggregates multi-source healthcare data, including medical imaging, EHRs, genomic information, and real-time data from wearable devices. The preprocessing phase addresses data quality by normalizing, selecting features, and augmenting data, ensuring heterogeneous inputs are suitable for model training while preserving clinical validity. The model training phase employs advanced AI techniques—including deep learning architectures, ensemble methods, and reinforcement learning—to address challenges such as class imbalance common in early and rare disease detection. The inference engine generates predictions, risk scores, and early warning alerts, providing interpretable outputs that support, rather than replace, clinician judgment. Finally, the clinical feedback loop enables continuous model refinement through physician validation, performance monitoring, and real-world outcomes, ensuring adaptability to evolving clinical practices and patient populations. Figure 1 illustrates this end-to-end pipeline and highlights the continuous learning cycle required to maintain both model accuracy and clinical relevance over time.

1.5. Structure of the Paper: How to Read This Review

The remainder of this paper is organized as follows. Section 2 outlines the review scope, methodology, and conceptual roles of artificial intelligence in early disease detection. Section 3 examines the clinical, operational, and systemic opportunities enabled by AI-driven healthcare systems, with attention to conditions under which diagnostic advantages emerge. Section 4 analyzes ethical, regulatory, and equity-related challenges that constrain real-world clinical adoption, emphasizing interdependencies between performance, governance, and trust. Section 5 proposes integration and implementation strategies, including operational mechanisms, governance structures, and architectural paradigms that support scalable and privacy-preserving deployment. Section 6 discusses near-term and long-term future directions, distinguishing implementation priorities from transformative ambitions. Section 7 presents policy implications and stakeholder-specific recommendations. Finally, Section 8 concludes the review by synthesizing key insights and articulating a translational framework for responsible and sustainable AI adoption in early disease detection.

2. Review Scope and Conceptual Framework

2.1. Review Methodology

This article adopts a structured narrative review methodology designed to ensure transparency, conceptual rigor, and interpretive coherence, without claiming formal compliance with systematic literature review (SLR) or PRISMA protocols. Rather than pursuing exhaustive enumeration, the literature selection was guided by conceptual relevance to the translation and adoption of AI in clinical settings. Inclusion criteria emphasized studies that:

- demonstrated clinical validation or real-world deployment,
- addressed early disease detection or pre-symptomatic risk prediction,
- had regulatory, ethical, or governance relevance, and
- contributed to system-level adoption readiness.

Studies were excluded if they lacked healthcare validation, relied exclusively on single-center or non-representative datasets, or duplicated higher-quality existing syntheses without providing new translational insight.

The technical capabilities reviewed in this section represent the foundational layer of the AI adoption pathway. However, algorithmic performance alone does not guarantee clinical utility. As discussed in Section 3, performance gains must translate into operational opportunities that meaningfully reduce diagnostic delay or workflow burden. These opportunities are subsequently constrained by ethical, regulatory, and data governance requirements (Section 4), and become clinically actionable when supported by appropriate implementation strategies and system architectures (Section 5), which together define the core adoption pathway examined in this review.

2.2. Conceptual Roles of Artificial Intelligence in Early Disease Detection

Rather than functioning as a monolithic diagnostic solution, artificial intelligence fulfills distinct conceptual roles within early disease detection workflows. Clarifying these roles is essential to avoid methodological overgeneralization and unrealistic performance expectations. Accordingly, this section reframes AI contributions by clinical function, treating specific algorithms and data modalities as enabling components rather than defining features.

2.2.1. AI as Diagnostic Augmentation

In its most established role, AI augments clinical interpretation by enhancing pattern recognition across complex, high-dimensional datasets. Image-based deep learning systems support radiologists and pathologists by highlighting suspicious regions, prioritizing abnormal cases, and reducing perceptual variability. In this role, AI does not replace clinical judgment; instead, it functions as a decision-support tool that improves consistency, throughput, and efficiency in high-volume diagnostic environments such as radiology and pathology.

2.2.2. AI as Predictive and Preventive Intelligence

Beyond diagnostic assistance, AI enables predictive and preventive intelligence, shifting healthcare from reactive treatment toward proactive risk management. Machine learning models trained on longitudinal EHRs, genomic data, and wearable sensor streams can estimate disease susceptibility before overt clinical manifestation. This role is particularly relevant for chronic and progressive conditions—including cardiovascular disease, diabetes, and neurodegenerative disorders—where early intervention can substantially alter disease trajectories and long-term outcomes.

2.2.3. AI as Clinical Workflow Orchestrator

AI also serves an important operational role by orchestrating clinical workflows and resource allocation. Triage algorithms prioritize urgent imaging studies, automate routine screening tasks, and streamline referral pathways. In this capacity, AI contributes indirectly to early disease detection by reducing diagnostic delays, minimizing clinician workload, and ensuring timely clinical intervention, rather than solely improving classification accuracy.

2.2.4. Supporting Methods and Data Modalities

A diverse ecosystem of algorithms and data sources enables these conceptual roles. Machine learning and deep learning models operate across medical imaging, clinical text, genomics, physiological signals, and real-time sensor data. Importantly, no single algorithmic method or data modality universally defines AI's role in early disease detection. Effectiveness depends on task specificity, data quality, population representativeness, and clinical integration context. Recognizing this dependency is essential for avoiding inflated or generalized claims of diagnostic superiority.

2.2.5. Performance Metrics of AI Models in Clinical Applications

Across specific clinical tasks, artificial intelligence models have demonstrated the ability to support early disease detection when evaluated under controlled, well-defined conditions. Rather than indicating universal diagnostic superiority, these studies illustrate how different AI approaches contribute to distinct functional roles within clinical workflows.

In medical imaging, deep learning–based convolutional neural networks have been applied to lung cancer screening using low-dose CT, demonstrating the feasibility of leveraging volumetric image information for early risk assessment in standardized screening settings [27]. In parallel, transformer-based natural language processing models have shown the ability to extract temporally structured clinical signals from unstructured electronic health records, enabling early identification of sepsis risk in longitudinal patient data [28].

Beyond imaging and text, machine learning applied to genomic and metabolic data has supported population-level risk stratification for chronic diseases such as type 2 diabetes, highlighting AI's role in predictive and preventive medicine rather than direct diagnosis [29]. In cardiovascular monitoring, recurrent neural network architectures trained on ECG time-series data have demonstrated reliable identification of cardiac rhythm patterns, supporting scalable decision support in high-volume monitoring environments [30]. Similarly, unsupervised and interpretable learning approaches have been explored for early detection of physiological deterioration and sepsis in intensive care settings by identifying anomalous trends in continuous vital-sign data streams [31]. Collectively, these studies illustrate the versatility of AI models across heterogeneous data modalities and clinical contexts. Importantly, the reported capabilities are task-specific and context-dependent, shaped by data quality, population characteristics, and clinical integration. As emphasized throughout this review, such findings should be interpreted as evidence of functional potential rather than as claims of universal clinical superiority. Table 1 summarizes representative AI approaches and their key qualitative findings, highlighting the diverse functional contributions of AI to early disease detection across imaging, clinical text, genomics, and physiological monitoring.

Table 1. AI Techniques and applications in early disease detection.

Study	AI Approach	Clinical Domain / Task	Key Qualitative Findings
Ardila et al. [27]	3D Deep CNN	Lung cancer screening (low-dose CT)	Demonstrated that end-to-end deep learning can leverage volumetric CT information to support early lung cancer risk assessment, highlighting the feasibility of AI-assisted screening in standardized imaging workflows.
Li et al.[28]	Transformer-based model	Longitudinal EHR representation	Showed that transformer architectures can capture temporal and contextual dependencies in longitudinal EHR data, enabling richer patient representations for downstream clinical risk modeling tasks.
Hahn et al. [29]	Machine learning on genomic and metabolic data	Type 2 diabetes risk stratification	Illustrated the integration of polygenic risk scores with metabolic profiles to support population-level disease risk stratification, emphasizing AI's role in predictive and preventive medicine rather than diagnosis alone.
Hannun et al. [30]	Deep neural network	Arrhythmia detection from ECG	Demonstrated that deep neural networks can reliably classify cardiac rhythm patterns from ambulatory ECG data, supporting scalable decision support in high-volume cardiac monitoring settings.
Nemati et al. [31]	Interpretable ML model	Early detection of sepsis in ICU	Highlighted the importance of interpretable machine-learning models for early physiological deterioration detection, showing that transparency can coexist with predictive utility in safety-critical clinical environments.

3. Opportunities of AI-Driven Healthcare

Artificial intelligence offers a range of opportunities to meaningfully enhance early disease detection when deployed in appropriate clinical and organizational contexts. These opportunities include improved diagnostic consistency, real-time monitoring for early intervention, increased operational efficiency, and expanded access to healthcare services in underserved regions [8], [9]. Importantly, the opportunities discussed in this section are not presented as standalone advantages of AI, but as enabling mechanisms that reduce translational friction between algorithm development and real-world clinical deployment. Each opportunity addresses a specific barrier to adoption—such as diagnostic variability, workforce constraints, or system inefficiency—thereby positioning AI capability within a broader implementation and governance context.

Figure 2 provides a conceptual overview of representative clinical domains in which AI has been applied to early disease detection, including oncology, cardiology, neurology, and infectious diseases. The depicted diagnostic tasks and indicative performance levels are synthesized from peer-reviewed benchmark studies and regulatory evaluations. The figure is intended to illustrate representative use cases and relative maturity of AI deployment rather than to imply uniform or universally superior performance. Reported accuracy, sensitivity, and predictive value are highly domain-specific and vary substantially across datasets, imaging protocols, patient populations, disease prevalence, and validation settings. Accordingly, comparative performance claims should be interpreted within the methodological constraints of individual studies and should not be extrapolated without external validation.



Figure 2. Conceptual overview of representative artificial intelligence (AI) application domains in early disease detection, including oncology, cardiology, neurology, and infectious diseases

3.1. Improved Diagnostic Accuracy

AI systems can enhance diagnostic consistency by reducing human error, inter-observer variability, and fatigue-related performance degradation. By providing reproducible interpretation across complex data streams, AI helps clinicians maintain consistent diagnostic standards, particularly in high-volume settings. In medical imaging, deep convolutional neural networks have demonstrated radiologist-level performance on chest radiographs, enabling the identification of abnormalities that might otherwise be overlooked [32]. In ophthalmology, deep learning models applied to retinal fundus images achieve high sensitivity and specificity for diabetic retinopathy and macular edema, supporting large-scale screening programs and expanding clinical coverage [33].

In oncology and pathology, AI models trained on whole-slide images assist pathologists by classifying tumor subtypes and predicting selected driver mutations, thereby supporting case prioritization and guiding downstream molecular testing [34]. AI-based triage systems further improve diagnostic workflows by ensuring that urgent cases—such as suspected pneumothorax or malignant biopsies—are reviewed promptly, contributing to standardized diagnostic thresholds across institutions [32], [34]. Collectively, these applications demonstrate how AI can enhance diagnostic accuracy as an augmentative tool, rather than as a replacement for clinical expertise.

3.2. Real-Time Monitoring and Early Intervention

When applied to continuous physiological and time-series data, AI enables earlier detection of clinical deterioration compared to intermittent monitoring approaches. Machine-learning–based sepsis prediction models that analyze EHRs and bedside vital signs can forecast the onset hours before clinical recognition, enabling timely intervention and improved patient outcomes [31]. Similarly, wearable electrocardiogram (ECG) devices and optical sensors facilitate near–real-time arrhythmia detection; for example, smartwatch algorithms can identify atrial fibrillation signals and prompt confirmatory ECG assessment [35].

These capabilities span multiple clinical domains, including neurology (e.g., motion- and EEG-based seizure or fall detection), infectious diseases (e.g., anomaly detection in vital-sign trends for early sepsis), and oncology (e.g., remote monitoring of chemotherapy-related physiological changes). Integration of streaming intensive care unit (ICU) data with AI-generated alerts allows subtle physiological trends to trigger early bedside review, potentially preventing

ICU transfers or cardiac arrest events [31], [35]. In this context, AI functions as an early warning system that complements clinical vigilance rather than substituting for it.

3.3. Cost Reduction and Operational Efficiency

AI-driven automation can reduce diagnostic turnaround times, lower operational costs, and free clinician time for direct patient care. In radiology, AI-assisted chest X-ray and CT triage systems decrease reporting backlogs by prioritizing critical studies and flagging abnormal findings. CheXNet-style models, for example, detect multiple thoracic pathologies with high sensitivity, reducing miss rates and accelerating clinical reporting workflows [12].

In pathology and oncology, AI-assisted slide scanning and pre-annotation shorten review times and support targeted molecular testing, thereby optimizing cost per diagnosis and improving laboratory efficiency [15]. Laboratory quality-control systems powered by AI reduce repeat testing and identify analytical outliers more rapidly. In infectious disease control, AI-driven screening tools—such as automated chest X-ray triage for tuberculosis—have demonstrated cost-effectiveness in high-burden regions by increasing case detection rates and shortening diagnostic cascades [18]. These examples illustrate how AI contributes to efficiency gains that are often prerequisites for sustainable adoption in resource-constrained healthcare systems.

3.4. Access to Underserved Regions

AI-enabled mobile diagnostics and telemedicine platforms extend specialist-level interpretation to low-resource and geographically remote settings. Autonomous diabetic retinopathy screening systems and portable AI-assisted chest X-ray devices enable earlier referral and on-site management in regions with limited access to trained clinicians [32], [33]. Infectious disease intelligence platforms further support early outbreak detection and public health prioritization through automated surveillance and trend analysis [36].

Cloud-based AI pathology services and smartphone-based cognitive screening tools allow remote access to oncology and neurology diagnostics, contributing to improved equity of care. For example, AI-based chest X-ray triage deployed in outreach tuberculosis screening programs flags high-risk cases for confirmatory testing, increasing detection rates while reducing dependence on scarce physician resources [29]. In these contexts, AI functions as a scalable diagnostic surrogate, partially mitigating structural inequalities in healthcare access.

3.5. AI and Human Clinicians: Complementary Roles in Diagnostic Workflows

Rather than establishing direct performance superiority, existing studies comparing artificial intelligence systems with human clinicians primarily examine how AI can complement clinical expertise under specific, controlled conditions. These comparisons are highly task-dependent and are shaped by evaluation protocols, data availability, and intended clinical use, such as screening, triage, or decision support.

In medical imaging–based screening tasks, AI systems have been evaluated alongside radiologists to assess their potential to reduce diagnostic workload, improve consistency, and assist in the identification of early disease signals. For example, deep learning models applied to breast cancer screening and pneumonia detection have been compared with expert readers in retrospective settings, often under constrained conditions that exclude broader clinical context, such as patient history or multimodal information. These studies do not aim to replace clinicians but rather to assess whether AI can function as a reliable second reader or pre-screening tool.

In other domains, including ophthalmology and cardiovascular monitoring, comparisons between AI models and clinicians have focused on task-specific operating points or workflow integration rather than global accuracy metrics. In such settings, AI systems are typically optimized for sensitivity or early detection, while clinicians retain responsibility for confirmatory diagnosis and clinical judgment. Importantly, the reported outcomes depend strongly on disease prevalence, dataset composition, and threshold selection, limiting direct transferability across clinical contexts.

Overall, the literature suggests that AI–human comparisons should be interpreted as contextual evaluations of complementary capabilities rather than as evidence of universal diagnostic superiority. Consequently, this review avoids aggregating quantitative performance metrics across heterogeneous tasks and instead emphasizes qualitative distinctions in evaluation settings, clinical roles, and deployment considerations. Table 2 summarizes representative studies that have explored AI–human comparisons, highlighting the clinical task, evaluation setting, and intended role of AI systems rather than numerical performance differences.

Table 2. Representative contexts of AI–human comparison across selected diagnostic tasks.

Clinical Task	AI System Role	Human Comparator	Evaluation Context	Key Comparative Insight
Breast cancer screening [37]	Reader assistance / second reader	Expert radiologists	Retrospective, multi-country screening datasets	AI was evaluated for its potential to reduce false positives and false negatives in controlled screening evaluations, rather than replacing radiologist judgment.
Pneumonia detection from chest X-ray [32]	Decision support	Academic radiologists	Controlled retrospective comparison with a limited clinical context	AI performance assessed relative to radiologists under constrained conditions, highlighting the feasibility of AI-assisted interpretation rather than standalone diagnosis.
Diabetic retinopathy screening [36]	Automated pre-screening	Trained graders/ophthalmologists	Task-specific operating points in screening settings	AI optimized for early detection sensitivity, with clinicians responsible for confirmation and treatment decisions.

3.6. Opportunities: Comparative Synthesis and Context-Dependent Performance Patterns

The diagnostic advantage of AI is most pronounced in high-volume, standardized screening tasks characterized by stable visual or signal-based biomarkers and abundant labeled data. In contrast, AI reliability decreases in atypical disease presentations, low-quality data environments, and clinical contexts requiring nuanced judgment, multimodal reasoning, or consideration of psychosocial factors. These limitations underscore the importance of hybrid intelligence frameworks, in which AI systems enhance efficiency and pattern recognition while clinicians retain contextual interpretation, accountability, and decision authority.

3.6.1. Conditions Where AI Excels

AI systems perform optimally when applied to high-quality, standardized imaging data—such as mammography, chest radiography, and retinal fundus imaging—where large, well-annotated datasets are available. They are particularly effective for diseases with stable and well-defined biomarkers, including breast cancer lesions and microaneurysms in diabetic retinopathy. AI also excels in high-throughput screening environments, maintaining accuracy without cognitive fatigue or inter-observer variability. In resource-constrained settings, AI serves as a scalable diagnostic adjunct, improving access to essential diagnostic services.

3.6.2. Conditions Where AI Underperforms or Fails

Despite strong aggregate performance, AI systems struggle with rare or atypical presentations that deviate from learned patterns, such as uncommon tumor morphologies or overlapping pathologies. Low-quality inputs, imaging artifacts, and population bias further compromise performance. Moreover, AI lacks context-dependent clinical reasoning, including the integration of patient history, comorbidities, and psychosocial factors. Models trained on static datasets may also fail to adapt to evolving disease patterns or changes in clinical practice. These limitations reinforce the need for continuous validation and clinician-in-the-loop deployment strategies.

4. Challenges: Interdependencies, Regulation, and Real-World Constraints

Despite its transformative promise, the integration of artificial intelligence into healthcare remains constrained by a set of interrelated ethical, regulatory, and technical challenges. These challenges—spanning data privacy, algorithmic bias, transparency, legal accountability, and clinical validation—require coordinated governance across jurisdictions to ensure patient safety, equity, and public trust [18], [29]. Importantly, these constraints do not operate in isolation; rather, they interact in ways that frequently stall real-world adoption despite promising algorithmic performance.

4.1. Interdependencies Between Performance, Data, and Clinical Context

The performance patterns associated with AI-based diagnostic systems do not reflect the intrinsic properties of algorithms alone; instead, they emerge from interdependent technical, organizational, and governance factors. As illustrated in Figure 3, ethical, legal, and regulatory challenges are not merely external barriers but systemic determinants of whether AI systems can be safely and effectively deployed in clinical environments.



Figure 3. Ethical, legal, and regulatory interdependencies shaping AI adoption in early disease detection

AI performance is strongly conditioned on data diversity, annotation quality, and population representativeness. Performance gains demonstrated in controlled experimental settings may deteriorate substantially when models are deployed across heterogeneous real-world institutions. Outcomes are further shaped by clinical workflow integration; systems introduced without structured clinician feedback loops risk misinterpretation, misuse, or abandonment. In addition, model-level considerations—such as algorithmic transparency, retraining frequency, and post-deployment monitoring—directly affect robustness and long-term reliability. Accordingly, the diagnostic advantages often attributed to AI systems should be interpreted as conditional on data quality, workflow design, and governance structures, rather than as universal or context-independent properties. Figure 3 highlights how misalignment among these elements explains why adoption frequently lags behind technical capability.

Figure 3 presents a systems-level conceptual illustration of an AI healthcare system for early disease detection and the interdependent challenges influencing its deployment. The central ellipse represents the operational AI system. Red rectangular blocks denote critical challenges—including data privacy, algorithmic bias, explainability, regulatory compliance, liability, and clinical validation—that directly constrain deployment (solid red arrows). Green rounded blocks represent mitigation strategies such as fair training datasets, data governance and anonymization, transparent algorithms, and legal frameworks. Dashed green arrows indicate policy- and governance-driven mitigation pathways that operate over time rather than immediate technical fixes. Blue dotted arrows capture interdependencies among challenges, illustrating how issues such as bias, explainability, privacy, and liability reinforce one another. The figure highlights how misalignment among technical performance, regulatory readiness, and clinical workflow integration stalls adoption despite promising algorithmic results.

4.2. Data Privacy and Security

AI systems depend on large-scale, often cross-border aggregation of sensitive healthcare data, creating heightened risks of privacy breaches and unauthorized access. According to the IBM Cost of a Data Breach Report (2023), the global average cost of a healthcare data breach reached USD 10.93 million, the highest across all sectors [38]. Sensitive data stored in EHRs, Internet of Medical Things (IoMT) devices, and cloud-based platforms are particularly vulnerable to cyberattacks, especially in low-infrastructure environments.

Regulatory and ethical frameworks such as the European Union General Data Protection Regulation (GDPR) and the EU AI Act (2024) mandate explicit consent, data minimization, and algorithmic traceability to mitigate these risks. Similarly, the WHO Ethics and Governance of AI for Health (2021) calls for harmonized global standards on data stewardship, encryption, and accountability for transnational healthcare datasets [39], [40]. These requirements significantly shape the feasibility and design of AI deployment strategies.

4.3. Algorithmic Bias and Equity

Algorithmic bias poses a substantial risk of amplifying existing healthcare inequities across race, gender, and geography. Empirical evidence from U.S. hospital systems revealed that an AI model underestimated the health needs of Black patients by nearly 40% due to reliance on cost-based proxies rather than direct measures of disease severity [12]. In low- and middle-income countries (LMICs), models trained predominantly on Western datasets frequently misclassify tropical or region-specific diseases, undermining diagnostic reliability for large populations.

To address these risks, regional and international frameworks—including the African Union Data Policy Framework (2022) and WHO ethical guidelines—advocate inclusive dataset design, fair representation, and continuous bias auditing throughout the AI lifecycle [5], [33]. Without such safeguards, AI-driven healthcare systems risk reinforcing structural inequities rather than alleviating them.

4.4. Explainability and Trust

Many deep learning systems operate as "black boxes," generating predictions without transparent rationale, which undermines clinician trust and acceptance. Surveys indicate that more than 60% of clinicians are hesitant to rely on opaque AI outputs in critical diagnostic scenarios [41]. Enhancing explainability through model-agnostic interpretability techniques—such as SHAP (Shapley Additive Explanations) and LIME (Local Interpretable Model-Agnostic Explanations)—can improve transparency and facilitate clinical validation [42], [43].

Regulatory guidance, including the U.S. FDA's Good Machine Learning Practice (GMLP) principles (2021), emphasizes traceability, model documentation, and human-in-the-loop oversight as prerequisites for the deployment of trustworthy AI. Ultimately, XAI frameworks help align predictive performance with clinical reasoning, professional accountability, and ethical responsibility.

4.5. Regulatory and Governance Challenges

The translation of AI's diagnostic advantages into routine clinical practice remains constrained by fragmented and evolving regulatory frameworks. In the United States, the FDA regulates AI diagnostic tools as Software as a Medical Device (SaMD), requiring rigorous premarket validation and continuous post-market surveillance—requirements that complicate the deployment of adaptive, continuously learning models. Similarly, the European Union Medical Device Regulation (EU MDR) mandates demonstrable clinical safety, transparency, and risk mitigation, often challenging for opaque deep learning systems.

In contrast, many regions in the Global South lack dedicated regulatory frameworks for medical AI, creating legal and ethical uncertainty despite AI's potential to address severe shortages of clinical expertise. Collectively, these regulatory frictions help explain why the diagnostic advantages highlighted in Figure 3 have not been uniformly translated into real-world clinical adoption.

4.6. Regional and Global Ethical Frameworks

The governance of AI in healthcare is increasingly shaped by converging global ethical norms. The European Union AI Act (2024) establishes legally binding obligations for transparency, risk management, and data integrity in high-risk healthcare applications [18]. The WHO Ethics and Governance of Artificial Intelligence for Health outlines six guiding principles: protection of autonomy, promotion of well-being, safety, transparency, accountability, and sustainability.

At the regional level, the African Union Data Policy Framework (2022) emphasizes equitable access to data, algorithmic fairness, and cross-border interoperability [39]. Complementary initiatives such as the OECD AI Principles (2019) and UNESCO's Recommendation on AI Ethics (2021) reinforce the need for human-centered, rights-based governance. Together, these frameworks aim to ensure that advances in AI-driven healthcare deliver societal benefit without exacerbating digital or health inequities.

Consequently, the diagnostic superiority attributed to AI systems—such as that illustrated in Figure 3—should be understood not as a replacement for clinical expertise, but as a performance-contingent augmentation shaped by data quality, regulatory oversight, and effective human–AI integration. These constraints directly inform the implementation strategies discussed in Section 5, which focus on translating technical capability into safe, accountable, and sustainable clinical adoption.

5. Integration and Implementation Strategies

This section synthesizes how technical capability, ethical governance, and organizational readiness converge to enable the real-world adoption of AI for early disease detection. To avoid conceptual overlap, implementation strategies are differentiated by their function in the adoption pathway. Sections 5.1–5.4 focus on operational, organizational, and governance mechanisms that enable clinical deployment. Section 5.5 presents representative case studies that illustrate translational feasibility rather than algorithmic novelty. Section 5.6 examines architectural paradigms that directly address privacy, scalability, and regulatory constraints. Finally, Section 5.7 integrates these elements into a set of adoption-oriented findings.

As highlighted in Figure 4, adoption failures often arise not from inadequate algorithmic performance but from misalignment between governance structures, workflow integration, and institutional readiness. Without these enabling conditions, even high-performing AI systems risk limited uptake, inequitable impact, or clinical harm [31], [35]. Figure 4 illustrates a translational roadmap in which diagnostic performance creates clinical opportunity, ethical and regulatory constraints limit translation, and targeted implementation strategies enable sustainable adoption.



Figure 4. Translational roadmap for AI adoption in early disease detection (opportunity → constraint → implementation → clinical outcomes).

5.1. Data Standardization and Interoperability

Data standardization is a foundational prerequisite for scalable and generalizable AI deployment in healthcare. Fragmented data silos, inconsistent terminologies, and heterogeneous imaging metadata remain major barriers to cross-institutional model portability and reproducibility. Rajkomar et al. demonstrated that models trained on non-standardized EHR data frequently fail when transferred across health systems due to variations in coding practices and clinical workflows [31].

International interoperability standards—such as HL7 Fast Healthcare Interoperability Resources (FHIR) and Digital Imaging and Communications in Medicine (DICOM)—provide structured frameworks for harmonizing clinical, laboratory, and imaging data. Adoption of these standards supports federated learning, multicenter validation, and regulatory compliance for AI systems operating across jurisdictions [32]. National initiatives, including the United Kingdom's NHS Artificial Intelligence Lab, demonstrate how standardized datasets can enable large-scale validation across oncology and radiology while preserving patient privacy [44]. Similarly, AI-driven infectious disease surveillance platforms rely on standardized epidemiological data exchange to support real-time outbreak detection and cross-border collaboration [36].

5.2. Interdisciplinary Collaboration

Effective AI integration requires sustained collaboration among clinicians, data scientists, engineers, ethicists, and policymakers. AI systems developed in isolation from clinical realities frequently fail to align with diagnostic reasoning, workflow constraints, or patient safety requirements. Interdisciplinary teams ensure that algorithmic outputs are interpretable, clinically meaningful, and actionable.

In neurology, collaboration between computational scientists and epileptologists has improved seizure prediction systems by integrating real-world EEG patterns with expert clinical annotation [44]. In oncology, radiogenomic modeling depends on close cooperation among radiologists, pathologists, and molecular biologists to validate biomarker associations and explainability [34]. Policymaker involvement is equally critical to ensure that reimbursement models, regulatory pathways, and liability frameworks evolve in parallel with technological capability [17].

Institutional innovation ecosystems—such as the Mayo Clinic Platform and NHS AI Centres of Excellence—illustrate how co-design environments facilitate simultaneous algorithm development, clinical trialing, and ethical evaluation, thereby reducing translational friction and accelerating safe adoption [4].

5.3. Capacity Building and Workforce Readiness

Human capacity development is essential for transforming AI from a novel technology into an operational clinical asset. Healthcare professionals must possess sufficient AI literacy to interpret outputs, recognize limitations, and exercise informed oversight. The World Economic Forum identifies AI and data literacy as critical skills for the future healthcare workforce [45].

Medical and nursing curricula should integrate foundational AI concepts, including data governance, algorithmic bias, model validation, and clinical risk assessment. Continuing professional development programs further equip practicing clinicians to supervise AI-assisted decision-making [46]. In low- and middle-income countries (LMICs), targeted digital literacy initiatives are particularly important for enabling adoption of AI tools in infectious disease control, maternal health, and primary care [47]. Workforce readiness thus functions as both a technical and ethical prerequisite for responsible AI deployment.

5.4. Ethical Oversight and Continuous Monitoring

Institutionalized ethical oversight mechanisms are indispensable for aligning AI deployment with principles of transparency, fairness, and patient autonomy. Healthcare organizations should establish AI ethics boards—analogous to institutional review boards (IRBs)—to evaluate algorithms before and after clinical deployment. These boards ensure compliance with international frameworks such as the WHO Ethics and Governance of AI for Health, the EU Artificial Intelligence Act, and national health data regulations [21], [48].

Post-deployment surveillance is especially critical for adaptive AI systems that evolve through continuous learning. Model drift, demographic shifts, and changes in clinical practice can degrade performance over time, necessitating ongoing monitoring and recalibration [23]. Transparent disclosure of AI use to patients—including consent for the secondary use of data—further strengthens trust and aligns with human rights–based governance principles [49]. Embedding ethics checkpoints across the AI lifecycle transforms ethical review from a one-time compliance exercise into a continuous accountability process.

5.5. Representative Case Studies of AI for Early Disease Detection

Table 3 presents representative case studies illustrating how AI systems have been operationalized for early disease detection across diverse clinical domains. These examples are selected to demonstrate translational feasibility rather than methodological novelty.

Table 3. Representative case studies of AI for early disease detection.

Case	AI System / Study	Clinical Context	Reported Performance Characteristics	Translational Status
Diabetic retinopathy screening [5]	Autonomous deep learning system	Primary care screening	Clinically validated autonomous detection meeting regulatory performance thresholds	Operational deployment (FDA-cleared)
Breast cancer screening (mammography) [37]	Deep learning ensemble	Population screening	Improved cancer detection and reduced false-positive recall when used as reader assistance	Clinical reader-assistance
Atrial fibrillation risk detection [50]	CNN-based ECG model	Opportunistic screening	Accurate retrospective identification of latent AF risk from sinus rhythm ECGs	Pre-deployment / risk stratification

As shown in Table 3, AI systems have achieved high diagnostic performance across modalities. However, consistent validation across diverse patient populations, transparent explainability, and integration into clinical workflows remain essential to ensuring safe, equitable, and generalizable adoption.

5.6. Federated Learning Architecture for Privacy-Preserving Healthcare AI

Federated learning is presented not merely as a technical architecture, but as an adoption-enabling mechanism that directly addresses privacy, regulatory, and cross-institutional data-sharing constraints. By enabling model training without centralized data aggregation, federated learning aligns with data protection regulations and supports scalable collaboration across healthcare systems.



Figure 5. Federated learning architecture enabling privacy-preserving and scalable AI adoption in healthcare.

Figure 5 illustrates a federated learning ecosystem in which hospitals train models locally using EHR, imaging, genomic, and wearable data. Only model parameters are shared with a central aggregator for secure averaging and synchronization, ensuring that raw patient data remain within institutional boundaries. Edge devices and mobile health applications extend analytics to the point of care, enhancing generalizability while preserving data sovereignty.

5.7. Integrative Synthesis of Key Findings

Across Sections 3–5, this review identifies five interdependent findings that shape the clinical adoption of AI for early disease detection. First, improvements in diagnostic accuracy and early risk prediction are necessary but insufficient for real-world impact without implementation strategies that address workflow integration and interoperability. Second, ethical and regulatory challenges—particularly algorithmic bias, limited explainability, and unclear accountability—act as binding constraints that directly moderate clinician trust and institutional uptake. Third, implementation mechanisms such as XAI, continuous performance auditing, and clinician training function as critical enablers that convert technical opportunity into clinical value. Fourth, evidence consistently favors human–AI collaboration over autonomous deployment, reinforcing AI's role as decision-support rather than a replacement for clinical judgment. Finally, sustainable adoption depends on lifecycle governance, recognizing AI systems as evolving socio-technical interventions requiring continuous oversight rather than static medical devices.

6. Future Directions: Near-Term and Long-Term Priorities

Future progress in AI-enabled healthcare depends on clearly distinguishing deployability challenges from transformational ambitions. While recent advances—such as generative models, digital twins, and hybrid quantum–classical learning—promise increased autonomy and predictive capability, their clinical value will ultimately depend on governance, validation, and integration rather than technical novelty alone [39], [48], [51].

In the near term (1–5 years), research and deployment efforts should prioritize safe and effective implementation. Key priorities include multicenter prospective validation, routine bias auditing across demographic and geographic subgroups, and explainability frameworks aligned with clinical reasoning rather than purely technical interpretability. Equally important is workflow-aware system design, ensuring that AI outputs reduce diagnostic delay and cognitive burden rather than introduce additional complexity. During this phase, emphasis should shift from marginal accuracy improvements toward robustness, accountability, and clinical usability.

In the long term (beyond 5 years), progress will depend on structural and systemic advances. These include adaptive and continuously learning AI systems operating under regulatory oversight, deeper multimodal integration of imaging, clinical, and longitudinal population data, and scalable population-level risk prediction. Embedding ethical constraints, auditability, and governance mechanisms directly into AI system architectures will be essential. Rather than isolated diagnostic tools, AI should evolve as a component of a learning healthcare ecosystem characterized by continuous evaluation, feedback, and institutional accountability. Together, these trajectories emphasize that future innovation must proceed in parallel with regulatory adaptation and post-deployment monitoring frameworks, ensuring that increasing algorithmic autonomy does not outpace clinical trust or societal oversight.

7. Policy Implications and Recommendations

Effective translation of AI into measurable public health benefits requires policies explicitly aligned with stakeholder roles across the healthcare ecosystem. A one-size-fits-all regulatory or institutional approach is insufficient given the socio-technical nature of AI deployment.

- Regulators should prioritize adaptive approval pathways and post-market surveillance mechanisms suitable for continuously learning systems, moving beyond static, one-time certification models.
- Healthcare institutions should invest in interoperability infrastructure, workforce training, and governance mechanisms that support ongoing monitoring, accountability, and clinician oversight.
- Developers should emphasize transparency, bias auditing, and workflow-aligned design, recognizing that clinical trust is a prerequisite for sustained adoption.

- Funders should support multicenter validation studies, longitudinal deployment research, and implementation science that bridges technical performance with real-world impact.

Across these stakeholders, the clinical value of AI will be determined not by benchmark performance alone, but by how responsibly systems are implemented, governed, and integrated into everyday care delivery.

8. Conclusion

This review demonstrates that the clinical adoption of artificial intelligence for early disease detection is shaped less by algorithmic performance in isolation than by the interactions among technical opportunity, ethical constraints, and implementation strategy. By synthesizing evidence across diagnostic capability, governance challenges, and deployment mechanisms, the review explains why many high-performing AI systems fail to achieve sustained clinical impact. A central contribution of this work is its functional reframing of AI as a pattern-recognition engine, a risk-stratification tool, and a clinician-facing decision-support partner embedded within healthcare systems. This integrative perspective moves beyond siloed technical or ethical analyses. It provides a translational roadmap for responsible adoption, particularly as generative and multimodal AI systems expand the scope of decision support while amplifying governance and trust considerations [10].

The review further clarifies persistent gaps in prior literature, including the tendency to overgeneralize diagnostic superiority and to underemphasize governance, generalizability, and real-world deployment constraints. By explicitly distinguishing AI's conceptual roles in diagnosis, prediction, and workflow orchestration, this work delineates where AI adds clinical value and where human oversight remains indispensable. Ultimately, the future of AI-driven early disease detection will depend not on autonomous intelligence alone, but on carefully designed human–AI systems grounded in transparency, inclusivity, and continuous validation. By integrating algorithmic capability, ethical accountability, regulatory feasibility, and implementation strategy within a unified analytical framework, this review provides a foundation for more rigorous evaluation, informed governance, and responsible deployment of AI in real healthcare environments.

Author Contributions: Conceptualization: A.S.E. and A.M.O.; Methodology: A.M.O.; Formal analysis: A.S.E.; Investigation: A.S.E.; Resources: A.S.E.; Data curation: A.S.E.; Writing—original draft preparation: A.S.E.; Writing—review and editing: A.M.O.; Visualization: A.S.E.; Supervision: A.M.O.; Project administration: A.M.O. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Data Availability Statement: Publicly archived datasets analyzed during this study are cited within the manuscript. No new primary datasets were generated for this research.

Acknowledgments: The authors gratefully acknowledge the constructive feedback provided by anonymous reviewers, whose insights significantly enhanced the rigor and clarity of this manuscript. Artificial intelligence tools were employed to support literature organization, language editing, and manuscript formatting. All scientific interpretations, analytical decisions, and conclusions were independently developed, verified, and approved by the authors, who assume full responsibility for the integrity and accuracy of the work.

Conflicts of Interest: The author declares that there is no conflict of interest regarding the research, authorship, or publication of this article.

References

[1] Z. Obermeyer and E. J. Emanuel, "Predicting the Future — Big Data, Machine Learning, and Clinical Medicine," *N. Engl. J. Med.*, vol. 375, no. 13, pp. 1216–1219, Sep. 2016, doi: 10.1056/NEJMp1606181.

[2] F. Jiang *et al.*, "Artificial intelligence in healthcare: past, present and future," *Stroke Vasc. Neurol.*, vol. 2, no. 4, pp. 230–243, Dec. 2017, doi: 10.1136/svn-2017-000101.

[3] A. Esteva *et al.*, "A guide to deep learning in healthcare," *Nat. Med.*, vol. 25, no. 1, pp. 24–29, Jan. 2019, doi: 10.1038/s41591-018-0316-z.

[4] E. J. Topol, "High-performance medicine: the convergence of human and artificial intelligence," *Nat. Med.*, vol. 25, no. 1, pp. 44–56, Jan. 2019, doi: 10.1038/s41591-018-0300-7.
[5] M. D. Abràmoff, P. T. Lavin, M. Birch, N. Shah, and J. C. Folk, "Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices," *npj Digit. Med.*, vol. 1, no. 1, p. 39, Aug. 2018, doi: 10.1038/s41746-018-0040-6.
[6] S. M. McKinney *et al.*, "International evaluation of an AI system for breast cancer screening," *Nature*, vol. 577, no. 7788, pp. 89–94, Jan. 2020, doi: 10.1038/s41586-019-1799-6.
[7] C. Damiani *et al.*, "Evaluation of an AI Model to Assess Future Breast Cancer Risk," *Radiology*, vol. 307, no. 5, Jun. 2023, doi: 10.1148/radiol.222679.
[8] P. Rajpurkar, E. Chen, O. Banerjee, and E. J. Topol, "AI in health and medicine," *Nat. Med.*, vol. 28, no. 1, pp. 31–38, Jan. 2022, doi: 10.1038/s41591-021-01614-0.
[9] Y. A. Fahim, I. W. Hasani, S. Kabba, and W. M. Ragab, "Artificial intelligence in healthcare and medicine: clinical applications, therapeutic advances, and future perspectives," *Eur. J. Med. Res.*, vol. 30, no. 1, p. 848, Sep. 2025, doi: 10.1186/s40001-025-03196-w.
[10] Z. L. Teo *et al.*, "Generative artificial intelligence in medicine," *Nat. Med.*, vol. 31, no. 10, pp. 3270–3282, Oct. 2025, doi: 10.1038/s41591-025-03983-2.
[11] D. S. Stamoulis and C. Papachristopoulou, "Artificial Intelligence in Radiology, Emergency, and Remote Healthcare: A Snapshot of Present and Future Applications," *J. Futur. Artif. Intell. Technol.*, vol. 1, no. 3, pp. 228–234, Oct. 2024, doi: 10.62411/faith.3048-3719-38.
[12] Z. Obermeyer, B. Powers, C. Vogeli, and S. Mullainathan, "Dissecting racial bias in an algorithm used to manage the health of populations," *Science (80-.).*, vol. 366, no. 6464, pp. 447–453, Oct. 2019, doi: 10.1126/science.aax2342.
[13] T. Eche, L. H. Schwartz, F.-Z. Mokrane, and L. Dercle, "Toward Generalizability in the Deployment of Artificial Intelligence in Radiology: Role of Computation Stress Testing to Overcome Underspecification," *Radiol. Artif. Intell.*, vol. 3, no. 6, Nov. 2021, doi: 10.1148/ryai.2021210097.
[14] N. Freyer, D. Groß, and M. Lipprandt, "The ethical requirement of explainability for AI-DSS in healthcare: a systematic review of reasons," *BMC Med. Ethics*, vol. 25, no. 1, p. 104, Oct. 2024, doi: 10.1186/s12910-024-01103-2.
[15] S. Tonekaboni, S. Joshi, M. D. McCradden, and A. Goldenberg, "What Clinicians Want: Contextualizing Explainable Machine Learning for Clinical End Use," in *Proceedings of Machine Learning Research*, Aug. 2019, pp. 1–21. [Online]. Available: http://arxiv.org/abs/1905.05134
[16] R. Rosenbacke, Å. Melhus, M. McKee, and D. Stuckler, "How Explainable Artificial Intelligence Can Increase or Decrease Clinicians' Trust in AI Applications in Health Care: Systematic Review," *JMIR AI*, vol. 3, p. e53207, Oct. 2024, doi: 10.2196/53207.
[17] U.S. Food and Drug Administration, "Good Machine Learning Practice for Medical Device Development: Guiding Principles," *FDA.gov*, 2025. https://www.fda.gov/medical-devices/software-medical-device-samd/good-machine-learning-practice-medical-device-development-guiding-principles
[18] European Commission, "European Artificial Intelligence Act comes into force," *European Commission*, 2024. https://digital-strategy.ec.europa.eu/en/news/european-artificial-intelligence-act-comes-force
[19] S. Reddy, "Generative AI in healthcare: an implementation science informed translational path on application, integration and governance," *Implement. Sci.*, vol. 19, no. 1, p. 27, Mar. 2024, doi: 10.1186/s13012-024-01357-9.
[20] A. Rajkomar, J. Dean, and I. Kohane, "Machine Learning in Medicine," *N. Engl. J. Med.*, vol. 380, no. 14, pp. 1347–1358, Apr. 2019, doi: 10.1056/NEJMra1814259.
[21] Z. Sadeghi *et al.*, "A review of Explainable Artificial Intelligence in healthcare," *Comput. Electr. Eng.*, vol. 118, p. 109370, Aug. 2024, doi: 10.1016/j.compeleceng.2024.109370.
[22] J. L. Raya-Povedano, "AI in breast cancer screening: a critical overview of what we know," *Eur. Radiol.*, vol. 34, no. 7, pp. 4774–4775, Dec. 2023, doi: 10.1007/s00330-023-10530-5.
[23] D. Windecker *et al.*, "Generalizability of FDA-Approved AI-Enabled Medical Devices for Clinical Use," *JAMA Netw. Open*, vol. 8, no. 4, p. e258052, Apr. 2025, doi: 10.1001/jamanetworkopen.2025.8052.
[24] A. Rocha *et al.*, "Edge AI for Internet of Medical Things: A literature review," *Comput. Electr. Eng.*, vol. 116, p. 109202, May 2024, doi: 10.1016/j.compeleceng.2024.109202.
[25] J. Biamonte, P. Wittek, N. Pancotti, P. Rebentrost, N. Wiebe, and S. Lloyd, "Quantum machine learning," *Nature*, vol. 549, no. 7671, pp. 195–202, Sep. 2017, doi: 10.1038/nature23474.
[26] B. Björnsson *et al.*, "Digital twins to personalize medicine," *Genome Med.*, vol. 12, no. 1, p. 4, Dec. 2020, doi: 10.1186/s13073-019-0701-3.
[27] D. Ardila *et al.*, "End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography," *Nat. Med.*, vol. 25, no. 6, pp. 954–961, Jun. 2019, doi: 10.1038/s41591-019-0447-x.
[28] Y. Li *et al.*, "BEHRT: Transformer for Electronic Health Records," *Sci. Rep.*, vol. 10, no. 1, p. 7155, Apr. 2020, doi: 10.1038/s41598-020-62922-y.
[29] S.-J. Hahn, S. Kim, Y. S. Choi, J. Lee, and J. Kang, "Prediction of type 2 diabetes using genome-wide polygenic risk score and metabolic profiles: A machine learning analysis of population-based 10-year prospective cohort study," *eBioMedicine*, vol. 86, p. 104383, Dec. 2022, doi: 10.1016/j.ebiom.2022.104383.
[30] A. Y. Hannun *et al.*, "Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network," *Nat. Med.*, vol. 25, no. 1, pp. 65–69, Jan. 2019, doi: 10.1038/s41591-018-0268-3.
[31] S. Nemati, A. Holder, F. Razmi, M. D. Stanley, G. D. Clifford, and T. G. Buchman, "An Interpretable Machine Learning Model for Accurate Prediction of Sepsis in the ICU," *Crit. Care Med.*, vol. 46, no. 4, pp. 547–553, Apr. 2018, doi: 10.1097/CCM.0000000000002936.

[32] P. Rajpurkar *et al.*, "CheXNet: Radiologist-Level Pneumonia Detection on Chest X-Rays with Deep Learning," *ArXiv*. Dec. 25, 2017. [Online]. Available: http://arxiv.org/abs/1711.05225
[33] V. Gulshan *et al.*, "Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs," *JAMA*, vol. 316, no. 22, p. 2402, Dec. 2016, doi: 10.1001/jama.2016.17216.
[34] N. Coudray *et al.*, "Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning," *Nat. Med.*, vol. 24, no. 10, pp. 1559–1567, Oct. 2018, doi: 10.1038/s41591-018-0177-5.
[35] M. V. Perez *et al.*, "Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation," *N. Engl. J. Med.*, vol. 381, no. 20, pp. 1909–1917, Nov. 2019, doi: 10.1056/NEJMoa1901183.
[36] J. T. Wu, K. Leung, and G. M. Leung, "Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study," *Lancet*, vol. 395, no. 10225, pp. 689–697, Feb. 2020, doi: 10.1016/S0140-6736(20)30260-9.
[37] S. M. McKinney *et al.*, "Addendum: International evaluation of an AI system for breast cancer screening," *Nature*, vol. 586, no. 7829, pp. E19–E19, Oct. 2020, doi: 10.1038/s41586-020-2679-9.
[38] IBM Security, "Cost of a Data Breach Report 2023," 2023. [Online]. Available: https://d110erj175o600.cloudfront.net/wp-content/uploads/2023/07/25111651/Cost-of-a-Data-Breach-Report-2023.pdf
[39] African Union, "AU Data Policy Framework," *African Union*, 2022. https://au.int/en/documents/20220728/au-data-policy-framework
[40] European Union, "Regulation (EU) 2024/1689 of the European Parliament and of the Council of 26 June 2024 laying down harmonised rules on artificial intelligence (Artificial Intelligence Act)," *EUR-Lex*, 2024. https://eur-lex.europa.eu/eli/reg/2024/1689/oj/eng
[41] M. Faiyazuddin *et al.*, "The Impact of Artificial Intelligence on Healthcare: A Comprehensive Review of Advancements in Diagnostics, Treatment, and Operational Efficiency," *Heal. Sci. Reports*, vol. 8, no. 1, Jan. 2025, doi: 10.1002/hsr2.70312.
[42] J. B. Oluwagbemi, O. V. Oyetayo, and E. O. Ibam, "SysFungiNet: A Multi-Omics Data Fusion Framework with Explainable AI for Bioactive Prioritization," *J. Futur. Artif. Intell. Technol.*, vol. 2, no. 4, pp. 661–679, Jan. 2026, doi: 10.62411/faith.3048-3719-304.
[43] T. R. Noviandy, G. M. Idroes, and I. Hardi, "An Interpretable Machine Learning Strategy for Antimalarial Drug Discovery with LightGBM and SHAP," *J. Futur. Artif. Intell. Technol.*, vol. 1, no. 2, pp. 84–95, Aug. 2024, doi: 10.62411/faith.2024-16.
[44] N. D. Truong *et al.*, "Convolutional neural networks for seizure prediction using intracranial and scalp electroencephalogram," *Neural Networks*, vol. 105, pp. 104–111, Sep. 2018, doi: 10.1016/j.neunet.2018.04.018.
[45] World Economic Forum, "The Future of Jobs Report 2023," Geneva, 2023. [Online]. Available: https://www.weforum.org/reports/the-future-of-jobs-report-2023
[46] Organisation for Economic Co-operation and Development, "AI principles," *OECD.org*, 2024. https://www.oecd.org/en/topics/ai-principles.html#:~:text=The OECD AI Principles promote,stand the test of time.
[47] UNESCO, "Recommendation on the Ethics of Artificial Intelligence," *unesco.org*, 2023. https://www.unesco.org/en/articles/recommendation-ethics-artificial-intelligence
[48] WHO guidance and World Health Organization, "Ethics and governance of artificial intelligence for health," *World Health Organization*, 2021. https://www.who.int/publications/i/item/9789240029200
[49] M. J. Sheller *et al.*, "Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data," *Sci. Rep.*, vol. 10, no. 1, p. 12598, Jul. 2020, doi: 10.1038/s41598-020-69250-1.
[50] Z. I. Attia *et al.*, "An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction," *Lancet*, vol. 394, no. 10201, pp. 861–867, Sep. 2019, doi: 10.1016/S0140-6736(19)31721-0.
[51] IBM, "Cost of a Data Breach Report 2023," 2023. [Online]. Available: https://www.ibm.com/reports/data-breach